Cause of Drug-induced Thrombocytopenic Purpura Identified by the Passive Transfer Reaction
Authors: HERBERT BERGER
Journal: Annals of Internal Medicine (1962)

Case Reports1 April 1962Cause of Drug-induced Thrombocytopenic Purpura Identified by the Passive Transfer ReactionHERBERT BERGER, M.D., F.A.C.P.HERBERT BERGER, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-56-4-618 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe agent responsible for secondary (non-idiopathic) thrombocytopenia can be readily identified if the patient has been exposed to only a single chemical. In some instances, however, the purpuric individual may have been using a multiplicity of drugs or been in direct contact with several potentially dangerous materials such as insecticides or arsenical rodent poisons. In such situations, identification of the offending chemical is difficult. The administration of a test dose to the patient may be hazardous or even fatal (1-3). Even a small amount of drug may cause a lysis of all circulating platelets, inhibit platelet formation by direct action...References1. ACKROYD JF: The pathogenesis of thrombocytopenic purpura due to hypersensitivity to sedormid. Clin. Sci. 7: 249, 1945. Google Scholar2. HIRSCHDAMESHEK EDW: Thrombocytopenic purpura due to allergy to quinidine. Amer. J. Med. 9: 828, 1950. CrossrefMedlineGoogle Scholar3. WEISFUSESPEARSASS LPWM: Quinidine induced thrombocytopenic purpura. Amer. J. Med. 17: 414, 1954. CrossrefMedlineGoogle Scholar4. CORN M: Personal communication. Google Scholar5. SHULMAN NR: Personal communication. Google Scholar6. MIALE JB: Laboratory Medicine and Hematology, The C. V. Mosby Company, St. Louis, 1958, p. 565. Google Scholar7. LARSON RK: The mechanism of quinidine purpura. Blood 8: 16, 1953. CrossrefMedlineGoogle Scholar8. STEFANINIDAMESHEK MW: The Hemorrhagic Disorders, Grune & Stratton, Inc., New York, 1955, pp. 112-114. Google Scholar9. ACKROYD JF: A simple method of estimating clot retraction and the changes that occur with menstruation. Clin. Sci. 7: 231, 1949. MedlineGoogle Scholar10. ACKROYD JF: The role of complement in sedormid purpura. Clin. Sci. 10: 185, 1951. MedlineGoogle Scholar11. FRIEDMANBARRBRODY ALPSEA: Hemozytic anemia due to quinidine; observations on its mechanism. Amer. J. Med. 20: 806, 1956. CrossrefMedlineGoogle Scholar12. FRIEDMANBRODYBARR ALEAPS: Immuno thrombocytopenic purpura due to quinidine. J. Lab. Clin. Med. 48: 205, 1956. MedlineGoogle Scholar13. HARRINGTONMINNICHHOLLINGSWORTHMOORE WSVJWCV: Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J. Lab. Clin. Med. 38: 1, 1951. MedlineGoogle Scholar14. SHULMAN NR: Immuno reactions involving platelets. I. A steric and kinetic model for formation of a complex from a human antibody, quinidine as a haptene, and platelets; and for fixation of complements by the complex. J. Exp. Med. 107: 665, 1958. CrossrefMedlineGoogle Scholar15. SHULMAN NR: Immuno reactions involving platelets. III. Quantitative aspects of platelet agglutination, inhibition of clot retraction, and other reactions caused by the antibody of quinidine purpura. J. Exp. Med. 107: 697, 1958. CrossrefMedlineGoogle Scholar16. SHULMAN NR: Immuno reactions involving platelets. IV. Studies on the pathogenesis of thrombocytopenia in drug purpura using test doses of quinidine in sensitized individuals; their implications for idiopathic thrombocytopenic purpura. J. Exp. Med. 107: 711, 1958. CrossrefMedlineGoogle Scholar17. SHULMAN NR: Abstract of proceedings of the 49th annual meeting of the American Society of Clinical Investigation. J. Clin. Invest. 36: 929, 1957. Google Scholar18. BIGELOWDESFORGES TSJF: Platelet agglutination by an abnormal plasma factor in thrombocytopenic purpura associated with quinidine ingestion. Amer. J. Med. Sci. 224: 274, 1952. CrossrefMedlineGoogle Scholar19. BARKHAMTOCANTINS PLM: Observations on the thrombocytopenia due to hypersensitivity to quinidine. Blood 9: 134, 1954. CrossrefMedlineGoogle Scholar20. GRANDJEAN LC: A case of purpura hemorrhagica after administration of quinine with specific thrombocytolysis demonstrated in vitro. Acta Med. Scand. (supp. 213) 131: 16, 1953. Google Scholar21. ROBSONDUTHIE HNJJ: Capillary resistance and adreno cortical activity. Brit. Med. J. 2: 971, 1950. CrossrefMedlineGoogle Scholar22. MACFARLANE RG: A simple method for measuring clot retraction. Lancet 1: 1199, 1939. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Staten Island, New YorkFrom the Richmond Memorial Hospital, Staten Island, New York.Requests for reprints should be addressed to Herbert Berger, M.D., The Berger Clinic, 7440 Amboy Road, Tottenville, Staten Island 7, New York. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByThrombopénies et leucopénies immuno-allergiques d'origine médicamenteuseAdverse Hematologic Effects of DrugsBIBLIOGRAPHYChange in Platelet Factor 3 as a Means of Demonstrating Immune Reactions Involving Platelets: Its Use as a Test for Quinidine-Induced ThrombocytopeniaObservations on Recipient Plasma Hemoglobin Concentration after Transfusion with Glycerolized Frozen Blood 1 April 1962Volume 56, Issue 4Page: 618-623KeywordsAllergensBone marrowDrugsHematology and oncologyInsecticidePlateletsResearch laboratories Issue Published: 1 April 1962 PDF DownloadLoading ...